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The highly immunosuppressive leporipoxvirus myxoma, previously was shown to promote the loss of cell surface class I
major histocompatibility complex (MHC I) molecules. Here, we show that myxoma virus induces the loss of both cell surface
and intracellular post-Golgi, b2-microglobulin-associated MHC I. Myxoma-induced loss of these MHC I molecules is
abrogated by vacuolar ATPase inhibitors, NH4Cl, and leupeptin. Furthermore, immunofluorescence microscopic studies
reveal that in myxoma-infected cells, b2-microglobulin-associated MHC I accumulates in Lamp-1
1 vesicular structures,
suggesting that myxoma virus targets MHC I for degradation in late endosomes and/or lysosomes. These events are
regulated by early gene product or products because they occur unabated in cells infected with myxoma virus in the
presence of cytosine arabinoside, an inhibitor of DNA synthesis. Studies with baby green monkey kidney cells transfected
with wild-type and tail-less forms of a mouse MHC I molecule, H-2Ld, indicate that the MHC I cytoplasmic tail is required for
myxoma-induced localization in Lamp-11 organelles. Myxoma-induced endocytosis and degradation of MHC I may provide
the virus with a means of dispensing with cell surface MHC I molecules that were loaded with peptides derived from viral
proteins synthesized early in infection. © 1999 Academic Press
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dINTRODUCTION
Immune responses to viral infections include the pro-
uction of neutralizing antibodies that bind to extracel-
ular virus and of virus-specific cytotoxic T lymphocytes
CTLs) that kill infected cells. CTL recognition of a virally
nfected cell occurs via the interaction of the T cell
eceptor for antigen with a trimolecular, membrane-
ound ligand on the surface of the infected cell (York and
ock, 1996). This trimolecular complex consists of a viral
eptide bound by a major histocompatibility complex
lass I (MHC I) molecule that itself is noncovalently
ssociated with a b2-microglobulin (b2-m) light chain
Madden, 1995). Assembly of the MHC I–peptide–b2-m
omplex involves several steps (Yewdell and Bennink,
992) and an array of cellular proteins that facilitate
omplex formation (Lehner and Cresswell, 1996). Protea-
ome-mediated degradation of cellular and viral proteins
ives rise to peptides that are delivered via the trans-
orter associated with antigenic processing (TAP) into
he endoplasmic reticulum (ER), where they then are
ound by newly synthesized MHC I–b2-m heterodimers
Heemels and Ploegh, 1995). On assembly, the MHC I
omplex is transported out of the ER and to the cell
urface, where it can be recognized by CTLs. Once at the
ell surface, some MHC I molecules are endocytosed
1 To whom reprint requests should be addressed. Fax: 831-459-3139.
c-mail: zuniga@darwin.ucsc.edu.
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180nd either recycled back to the plasma membrane (Ab-
el Motal et al., 1993; Reid and Watts, 1990) or retained
ntracellularly and degraded. Hence, maintenance of
teady-state levels of functional MHC I complexes at the
ell surface is achieved by a balance of several pro-
esses: the synthesis and exocytic transport of newly
ynthesized MHC I molecules, the recycling of endocy-
osed peptide-associated MHC I molecules, and the
egradation of denatured MHC I molecules that have
ost antigenic peptides.
Several viruses have evolved strategies for evading
TL-mediated immunity by interfering with the cell sur-
ace display of MHC I (McFadden and Kane, 1994;
loegh, 1998). A variety of mechanisms have been iden-
ified. The ICP47 gene product of herpes simplex virus 1
HSV-1) (Fruh et al., 1995; Hill et al., 1995; Tomazin et al.,
996; York et al., 1994) and the US6 protein of human
ytomegalovirus (HCMV) (Ahn et al., 1997; Hengel et al.,
996) block peptide import by TAP. The E3/19K protein of
denovirus (Andersson et al., 1985; Burgert and Kvist,
985; Cox, Bennink, and Yewdell, 1991) and the US3
rotein of HCMV (Ahn et al., 1996b; Jones et al., 1996)
etain MHC I molecules in the ER. The HCMV proteins
S11 and US2 promote the extrusion of ER-resident
HC I into the cytosol, where it is then degraded by
roteasomes (Ahn et al., 1996a; Jones and Sun, 1997;
iertz et al., 1996). The Nef protein of human immuno-
eficiency virus-1 (HIV-1) promotes the endocytosis of
ell surface MHC I and retargets Golgi-resident MHC I
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181DEGRADATION OF CELL-SURFACE CLASS I MHColecules (Greenberg et al., 1998; Le Gall et al., 1998;
angasarian et al., 1997), leading to their degradation
ia lysosomal mechanisms (Schwartz et al., 1996).
ence, it appears that virtually any step in MHC I as-
embly and transport is vulnerable to viral sabotage.
Pox viruses are particularly adept at evading immuno-
urveillance. The genomes of these large DNA viruses
ncode a variety of immunomodulatory molecules that
everely impair host antiviral responses (McFadden,
998; McFadden et al., 1996, 1995). One poxvirus, rabbit
yxoma virus, is of particular interest because it can be
tudied experimentally both on the molecular level and in
ivo (Barry et al., 1997; Mossman et al., 1996a, 1996b).
yxoma causes systemic immunosuppression and en-
uing death in infected European rabbits (McFadden and
ane, 1994). A potentially immunosuppressive effect of
yxoma and of the highly related malignant rabbit fi-
roma virus (MRV) is the down-regulation of cell surface
HC I in infected cells (Boshkov et al., 1992). Rescue of
ell surface MHC I display by cytosine arabinoside (Ara-
), an inhibitor of DNA replication (Levitt and Becker,
967), is incomplete. Because inhibition of DNA synthe-
is prevents late gene expression, these results sug-
ested the involvement of both early and late viral genes
Boshkov et al., 1992) and the possibility of multiple
echanisms in the abrogation of MHC I expression in
yxoma virus- and MRV-infected cells.
We present evidence showing that the loss of b2-m-
ssociated MHC I molecules from the surfaces of myx-
ma-infected cells is due in part to its accumulation and
egradation in late endosomes and/or lysosomes, iden-
ified by the fact that they contain Lamp-1, a protein
haracteristic of these compartments. In contrast, trans-
errin receptors (TRs), which cycle through early endo-
omes (Fuller and Simons, 1986; May and Cuatrecasas,
985; van Weert et al., 1995), do not undergo myxoma-
nduced concentration into late endosomes/lysosomes
r degradation. Although MHC I degradation occurs
ather late in myxoma infection, Ara-C neither prevents
ccumulation of MHC I molecules in Lamp1 structures
or relieves its degradation. Hence, these processes are
ediated by early viral gene products. A transfected
ouse MHC I molecule, H-2Ld, is lost from the surfaces
f myxoma-infected baby green monkey kidney (BGMK)
ells just as endogenous MHC I molecules are (Zu´n˜iga
t al., 1999) and becomes localized in Lamp-11 late
ndosomes/lysosomes. In contrast, myxoma virus infec-
ion has no effect on the intracellular distribution of a
ail-less mutant of H-2Ld. These results show that fea-
ures within the cytoplasmic tail of MHC I are required for
yxoma-induced retention within Lamp-11 cellular struc-
ures.
Myxoma virus-induced redistribution and degradation
f MHC I molecules may enable this virus to eliminate
iral peptide-loaded MHC I molecules that were trans- torted to the cell surface before other viral mechanisms
f MHC I down-regulation are fully effective.
RESULTS
yxoma virus induces degradation of MHC I
olecules
Previous studies showed that MHC I molecules are
ost from the surfaces of BGMK cells infected with either
yxoma virus or MRV (Boshkov et al., 1992). Flow cytom-
try analysis revealed a reduction in cell surface MHC I
n MRV-infected BGMK cells as early as 4 h postinfection
p.i.) (Boshkov et al., 1992). In the present study, we used
cell surface radioimmunoassay (RIA) to assess the
evels of cell surface MHC I in cells infected with myx-
ma virus, which shares 95% sequence homology with
RV. At 3 and 6 h p.i., cell surface MHC I levels not only
emain high but actually increase slightly (Fig. 1 A). Cell
urface levels of MHC I drop dramatically by 18 h p.i. and
ecline even further by 24 h p.i. (Fig. 1 A). (The levels of
ell surface MHC I at 12 h p.i. are intermediate between
hose observed in cells that were infected for 6 h and
FIG. 1. Myxoma virus induces loss of cell surface MHC I from
nfected BGMK cells. (A) Cell surface RIA of MHC I in myxoma-infected
GMK cells that were mock-infected or infected with 10 PFU/cell
Myxlac for the time periods indicated and plated in quadruplicate (104
ells/well) in a microtiter plate. Cell surface MHC I was detected by
ncubating cells (p.i.) with 10 mg/ml MAb W6/32 for 1 h at 4°C followed
y incubation with 5 3 105 cpm/well 125I-labeled goat anti-mouse IgG
nder the same conditions. Data shown are from two independent
xperiments. (B and C) Flow cytometric analysis of surface and total
ellular MHC I in vMyxlac-infected BGMK cells at 24 h p.i. (B) Overlay
istograms of cell surface W6/32 staining of intact mock- and vMyxlac-
nfected cells. (C) W6/32 staining of permeabilized mock- and vMyxlac-
nfected cells. Data were acquired on 10,000 cells/sample with light
catter signals at linear gain and fluorescence signals at logarithmic
ain. (B and C) The black peak represents the vMyxlac-infected cells,
hereas the white peak represents the mock-infected cells.hose infected for 18 h; data not shown.) As reported
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182 ZU´N˜IGA ET AL.reviously (Boshkov et al., 1992) the loss of cell surface
HC I does not correlate with a reduced viability of
nfected cells. Indeed, the viability of all cell populations
sed in the RIA studies is greater than 90% (data not
hown). Flow cytometric analyses of myxoma-infected
ells (Fig. 1B) show that the loss of cell surface MHC I is
haracteristic of the entire cell population and is accom-
anied by a comparable loss of intracellular MHC I (Fig.
C). The loss of MHC I is not due to inhibition of host
rotein synthesis by myxoma virus because the reduc-
ion in cell surface MHC I in myxoma-infected cells is
uch greater than that observed for cells treated with
he protein synthesis inhibitor cycloheximide (Boshkov et
l., 1992; Zu´n˜iga et al., 1999).
We next examined the effect of myxoma virus infection
n the stability of MHC I molecules that were synthe-
ized before infection. In previous studies, we observed
hat newly synthesized MHC I molecules are transported
o the cell surface within 2 h of their synthesis and are
till detectable up to 24 h after their synthesis (Zu´n˜iga et
l., 1999). Accordingly, BGMK cells were labeled for 1 h
ith EXPRE35S35S and then mock or myxoma infected for
, 12, or 24 h in complete medium. MHC I molecules
ere immunoprecipitated with monoclonal antibody
MAb) W6/32, which is specific for b2-m-associated MHC
FIG. 2. Myxoma virus induces loss of biosynthetically labeled MHC
in BGMK cells. BGMK cells were pulse labeled with EXPRE35S35S for
h, then either lysed directly (0 -h chase) or chased in complete growth
edium for 4 (A), 12 (B, lanes 1 and 2), or 24 (B, lanes 3 and 4; C, lanes
–3) h in the absence or presence of 10 PFU/cell vMyxlac as indicated.
HC I or transferrin receptor (TR) molecules were immunoprecipitated
ith the antibodies indicated in each of the panels. (A and B) Immu-
oprecipitated proteins were digested with endo H. SDS–PAGE was
erformed under nonreducing conditions. The positions of endo H-
esistant (EHR) and endo H-sensitive (EHS) MHC I, b2-m, and TR are
ndicated by arrows. (C) Lane 1 shows proteins that bind to protein
–Sepharose in the absence of anti-TR antibody, and the positions of
he 200- and 135-kDa molecular weight markers are indicated to the
ight of lane 3.molecules. Immunoprecipitates were treated with en- toglycosidase H (endo H) before analysis by SDS–PAGE
o determine the proportion of MHC I molecules that had
raversed the medial-Golgi by the end of each chase/
nfection period. At the end of the 1-h biosynthetic label-
ng period, approximately 50% of the W6/32-reactive
HC I molecules in uninfected BGMK cells are endo H
esistant (Fig. 2A, lane 1), but by 4-h chase, these MHC
molecules are all endo H resistant (Fig. 2A, lane 2).
ndo H-resistant, W6/32-reactive MHC I molecules per-
ist in uninfected cells as long as 12 and even 24 h after
iosynthetic labeling (Fig. 2B, lanes 1 and 3).
Myxoma virus infection has no effect on the stability of
6/32-reactive (i.e., b2-m-associated) MHC I molecules
uring the first 4 h of infection (Fig. 2A, compare lanes 2
nd 3). However, at 12 h p.i., the amount of biosyntheti-
ally labeled W6/32-reactive MHC I is only 50% of that
bserved in mock-infected cells (Fig. 2B, compare lanes
and 2) and has dropped further by 24 h p.i. (Fig. 2B,
ompare lanes 3 and 4). In contrast, the amount of
ransferrin receptor (TR) is identical in mock- and myxo-
a-infected BGMK cells at 24 h p.i. (Fig. 2C, compare
anes 2 and 3). Hence, myxoma virus infection does not
ffect the stability of TR but gradually renders b2-m-
ssociated MHC I molecules unstable.
he myxoma-induced loss of post-Golgi MHC I
olecules is mediated by early gene products
Because MHC I degradation is not evident until rela-
ively late in infection, we sought to determine whether
egradation is mediated by early or late viral gene prod-
cts (or both). BGMK cells were labeled with
XPRE35S35S and then mock infected or infected with
yxoma virus for 24 h in the absence and presence of
ra-C. As shown in Fig. 2B, lane 3, at the end of a 24-h
hase period, W6/32-reactive MHC I molecules are ex-
lusively endo H resistant. This is also true in Ara-C-
reated cells (data not shown). The treatment of cells with
ra-C results in an increase in the amount of W6/32-
eactive MHC I regardless of myxoma virus infection (Fig.
, compare lanes 1 and 2 and lanes 3 and 4). Quantitative
ensitometry of gels such as that shown in Fig. 3 con-
FIG. 3. Ara-C does not prevent degradation of assembled MHC I
olecules in myxoma-infected BGMK cells. BGMK cells were pulse
abeled with EXPRE35S35S for 1 h and chased for 24 h in the absence or
resence of 10 PFU/cell vMyxlac. In the samples in lanes 2 and 4,
ra-C was added 1 h p.i. to a final concentration of 40 mg/ml. MHC I
olecules were immunoprecipitated with MAb W6/32. The position ofhe MHC I heavy chain (HC) is indicated.
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183DEGRADATION OF CELL-SURFACE CLASS I MHCirms that the relative amount of MHC I in Ara-C-treated
ells relative to untreated cells is equivalent in myxoma-
nfected and uninfected cells (data not shown). Hence,
lthough the degradation of post-Golgi MHC I molecules
s not maximal until late in infection, it appears to be
ediated by early myxoma gene products.
haracteristics of degradation of assembled MHC I
olecules in myxoma virus-infected cells
The apparent loss of post-Golgi, b2-m-associated
HC I in myxoma-infected cells might be due to MHC I’s
issociation from b2-m, thereby leading to loss of reac-
ivity with W6/32 or to its degradation. To distinguish
etween these possibilities, we assessed the recovery
f biosynthetically labeled, W6/32-reactive MHC I from
GMK cells infected in the presence of protease inhibi-
ors or of drugs that perturb acidic compartments. A
pecific inhibitor of proteasomes, ZL3VS (Bogyo et al.,
997); the lysosomotropic agent NH4Cl; the vacuolar
TPase inhibitor bafilomycin A1 (Baf) (Woo et al., 1992b)
r concanamycin A (CCA); the serine protease inhibitor
eupeptin; or the acid protease inhibitor pepstatin A was
dded to the cells at 4 h p.i. as described in Materials
FIG. 4. Myxoma-induced degradation of MHC I is rescued by inhibito
C) cells were pulse labeled with EXPRE35S35S for 1 h and chased in co
n the absence and presence of 10 PFU vMyxlac. Then 40 mM NH4Cl, 2
t 4 h p.i. where indicated. (A and B) MHC I molecules were immunopre
f samples in B), and resolved by SDS–PAGE. The positions of the M
-sensitive (EHS) MHC I heavy chain (B) are indicated. (C) MHC
oimmunoprecipitated with MHC I, is not shown. (D) Mean fluorescenc
fter mock or vMyxlac infection in the presence or absence of NH4Cl. In
egend to Fig. 1 except that infection was for 12 h. Where indicated, Nnd Methods and included for the duration of the chase (eriod. The addition of the drugs at 1–4 h p.i. does not
nterfere with viral infection, and more than 90% of cells
ere infected under all experimental conditions (data not
hown). Consistent with the data in Fig. 2B, myxoma
irus infection for 24 h in the absence of protease inhib-
tors results in a dramatic loss of 35S-labeled, W6/32-
eactive MHC I molecules (Fig. 4A, compare lanes 1 and
). This loss is not prevented by ZL3VS (Fig. 4A, compare
anes 3 and 4), indicating that myxoma virus-induced
egradation of post-Golgi MHC I does not involve pro-
easomes. In contrast, degradation of W6/32-reactive
HC I in myxoma-infected BGMK cells is prevented by
he vacuolar ATPase inhibitors Baf (Fig. 4A, compare
anes 5 and 6) and CCA (data not shown) and by NH4Cl
Fig. 4B, compare lanes 3 and 4). Although it is difficult to
btain consistently adequate resolution of endo H-resis-
ant from endo H-sensitive forms of MHC I, the data in
ig. 4B show that MHC I molecules that are rescued from
egradation by NH4Cl are entirely endo H resistant.
hese results indicate that post-Golgi, assembled MHC
molecules are degraded in lysosomes and/or late en-
osomes. Interestingly, leupeptin rescues W6/32-reac-
ive MHC I from degradation in myxoma-infected cells
sosomal proteases and of vacuolar ATPase. BGMK (A and B) or RK-13
growth medium for 0 h (B, lane 1) or 24 h (all other gel lanes in A–C)
CA, 10 mM leupeptin, 100 mM pepstatin A, or 5 mM ZL3VS was added
d from cell lysates with MAb W6/32, digested with endo H (in the case
eavy chain (HC) (A and C) and of endo H-resistant (EHR) and endo
cules were immunoprecipitated with MAb anti-61; b2-m, which is
ity of cell surface (bars 1–4) and total MHC I (bars 5–8) in BGMK cells
with vMyxlac and flow cytometry were performed as discussed in the
as added to a final concentration of 40 mM at 1 h p.i.rs of ly
mplete
5 nM C
cipitate
HC I h
I mole
e intens
fection
H4Cl wFig. 4A, compare lanes 7 and 8), whereas pepstatin A
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184 ZU´N˜IGA ET AL.oes not (Fig. 4A, compare lanes 9 and 10), indicating
hat their degradation is mediated by serine proteases
ut not by cathepsin D.
In the rabbit cell line RK-13, MHC I molecules are lost
n myxoma virus infection (Fig. 4C, compare lanes 1 and
), and this loss of MHC I is prevented when CCA is
dded 4 h p.i. (Fig. 4C, compare lanes 3 and 4). A
ransfected mouse MHC I molecule, H-2Ld, also is lost
rom surfaces of myxoma-infected BGMK cells (Fig. 7).
ence although myxoma virus has been shown to infect
nly rabbit and BGMK cells, it nevertheless promotes the
oss of a variety of MHC I molecules of different species
rigins.
It was of interest to determine whether drugs that
escue MHC I from degradation also rescue its cell
urface display in myxoma-infected cells. This question
as addressed by flow cytometric analysis of intact and
ermeabilized BGMK cells. Mock- or myxoma-infected
GMK cells were treated with 40 mM NH4Cl at 1 h p.i. or
ere left untreated and then were analyzed for cell sur-
ace and intracellular MHC I by flow cytometry. Both cell
urface and intracellular levels of MHC I drop after a 12-h
nfection with myxoma virus (Fig. 4D, compare bars 1 and
and 5 and 6, respectively). In agreement with the
mmunoprecipitation data in Fig. 4B, NH4Cl rescues in-
racellular levels of MHC I (Fig. 4D, compare bars 6 and
). However, NH4Cl does not prevent the loss of cell
urface MHC I in myxoma-infected cells (Fig. 4D, com-
are bars 2 and 4). In interpreting this result, it is impor-
ant to note that neither cell surface nor intracellular
evels of MHC I are affected by NH4Cl in mock-infected
ells even after 11-h treatment (Fig. 4D, compare bars 1
nd 3). Hence, myxoma virus promotes the internaliza-
ion of MHC I molecules and their retention within cells
n a manner that is independent of their degradation.
yxoma-induced localization of MHC I molecules
n late endosomes/lysosomes
To identify the cellular sites of myxoma-induced MHC
retention, immunofluorescence microscopy was per-
ormed on permeabilized mock- and myxoma-infected
GMK cells at 24 h p.i. Immunostaining was performed
s described in Materials and Methods, with single im-
unostaining being done in the case of transferrin re-
eptor, a molecule whose cell surface expression is
naffected by myxoma virus infection (Boshkov et al.,
992), and double immunostaining being done to detect
oth MHC I and Lamp-1 (Akasaki et al., 1995), a protein
haracteristic of late endosomes and lysosomes (Rabi-
owitz et al., 1992), in the same cell samples. Under the
onditions used, staining of cell surface proteins is dif-
icult to discern, but intracellular staining is good. The
ntracellular distribution of transferrin receptor is identi-
al in mock- and myxoma-infected cells (Figs. 5A and
B). Similarly, the intracellular distribution of Lamp-1 is Iot markedly affected by myxoma virus infection and
ccurs in both a perinuclear array and in vesicular struc-
ures (Figs. 5E and 5F). In contrast, myxoma virus infec-
ion induces a striking change in the localization of MHC
. W6/32-reactive MHC I is widely distributed in a large
erinuclear array in mock-infected BGMK cells (Fig. 5C),
hereas in cells infected with myxoma virus for 24 h, it is
ocalized in discrete vesicles (Fig. 5D). Superimposition
f the images shown in Figs. 5C and 5E and in Figs.5D
nd 5F, respectively, was done to examine co-localization
f MHC I and Lamp-1. In uninfected cells, MHC I co-
ocalizes with Lamp-1 only in the perinuclearly distrib-
ted Golgi (Fig. 5G), as would be expected for two mol-
cules that traverse the Golgi during their biosynthesis.
n contrast, in myxoma-infected cells, MHC I co-localiza-
ion with Lamp-1 is almost exclusively in vesicular struc-
ures, presumably endolysosomal compartments (Fig.
H).
The effect of Ara-C on the myxoma-induced redistri-
ution of W6/32-reactive MHC I molecules in cells also
as examined by immunofluorescence microscopy. As
n the studies shown in Fig. 5, double immunostaining
as performed for the simultaneous detection of MHC I
nd Lamp-1. W6/32-reactive MHC I molecules localize in
esicular structures in BGMK cells infected with myxoma
irus in the presence of Ara-C (Figs. 6D and 6F) just as
hey do in cells infected in the absence of this inhibitor
Figs. 6A and 6C). These vesicular structures are
amp-11 (Figs. 6B, 6C, 6E, and 6F). These results are
onsistent with the data in Fig. 3 showing that Ara-C
oes not prevent the degradation of post-Golgi, W6/32-
eactive MHC I molecules and support the conclusion
hat MHC I localization into late endosomes and/or lyso-
omes and its degradation therein are dependent on the
unction of early viral gene products. Parenthetically,
hese immunofluorescence microscopic studies reveal
hat Ara-C rescues the myxoma-induced loss of pe-
inuclearly distributed MHC I (compare Figs. 6D and 6F
ith Figs. 6A and 6C). The rescue of perinuclearly dis-
ributed MHC I by Ara-C suggests that late viral gene
roducts prevent MHC I egress from the ER. Indeed, TAP
unction is abrogated late in myxoma infection (M. C.
u´n˜iga and H. Wang, unpublished observations).
he MHC I cytoplasmic domain is required
or myxoma-induced localization in late endosomes/
ysosomes
The evidence presented thus far suggests that in myx-
ma-infected cells, post-Golgi MHC I molecules are re-
ained in late endosomes and/or lysosomes, where they
re degraded. At least some of the MHC I molecules that
re retained intracellularly are likely to have been endo-
ytosed from the cell surface because the decline in cell
urface MHC I and the degradation of MHC I are similar.n previous work, we observed that the MHC I cytoplas-
I
i
d
B
a
i
c
F
B
185DEGRADATION OF CELL-SURFACE CLASS I MHCFIG. 5. MHC I molecules accumulate in late endosomes/lysosomes in myxoma-infected BGMK cells. The intracellular distribution of TR and MHC
in mock (A, C, E, and G) and vMyxlac-infected BGMK (B, D, F, and H) cells was examined by immunofluorescence microscopy at 24 h p.i. as described
n Materials and Methods. Then b2-m-associated MHC I was detected with MAb W632, followed by FITC-GAMIG (C, D, G, and H), Lamp-1 was
etected with anti-Lamp-1, followed by Rh-GARIG (E–H), and TRs were detected with anti-transferrin receptor MAb, followed by FITC-GAMIG (A and
). (A and B) Distribution of TR. (C and D) Distribution of W6/32-reactive MHC I. (E and F) Staining with anti-Lamp-1. (G and H) Merged images of C
nd E and of D and F, respectively. The scale bar represents 25 mm.FIG. 6. Myxoma-induced accumulation of MHC I in late endosomes/lysosomes is not dependent on late viral gene expression. BGMK cells were
nfected with 10 PFU/cell vMyxlac in the absence (A–C) or presence (D–F) of 40 mg/ml Ara-C. At 24 h p.i., cells were processed for immunofluores-
ence microscopy as described in Materials and Methods. Then b2-m-associated MHC I molecules were detected with MAb W6/32, followed by
ITC-GAMIG A, C, D, and F), and Lamp-1 was detected with anti-Lamp-1, followed by Rh-GARIG (B, C, E, and F). (C and F) Merged images of A and
and of D and E, respectively. The scale bar represents 25 mm.
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186 ZU´N˜IGA ET AL.ic tail is not required for transport of newly synthesized
olecules to the cell surface but that it does influence
HC I endocytosis (Capps et al., 1989; Zu´n˜iga and Hood,
986; Zu´n˜iga et al., 1983). A requirement for the cytoplas-
ic tail during endocytosis is consistent with evidence
rom other studies showing that cell surface proteins are
ecruited into coated pits as a consequence of interac-
ions between their cytoplasmic domains and adaptins
Beltzer and Spiess, 1991; Glickman et al., 1989). We
easoned that if some of the MHC I molecules that
ocalize in Lamp-11 structures in myxoma-infected cells
ere derived from the cell surface by endocytosis, then
HC I molecules that lack intact cytoplasmic tails may
scape such virus-induced localization. To test this pos-
ibility, we generated BGMK cell lines transfected with
he gene encoding the mouse MHC I molecule H-2Ld.
IAs show that cell surface H-2Ld declines by 80% in
yxoma-infected BGMK cells by 24 h p.i. (Fig. 7). Indeed,
he amount of radioiodinated H-2Ld-specific antibody
ound by myxoma-infected BGMK-Ld transfectants is
quivalent to that bound by nontransfected BGMK cells
FIG. 7. Cell surface RIA of cell surface mouse H-2Ld MHC I in
yxoma-infected transfectant BGMK cells. BGMK-Ld transfectants
ere mock infected (BGMK-Ld mock) or infected with 10 PFU/cell
Myxlac (BGMK-Ld 1 myx) for 24 h and plated in triplicate (104 cells/
ell) in a microtiter plate. Cell surface H-2Ld was detected by incubat-
ng cells (p.i.) with 10 mg/ml MAb 30.5.7 for 1 h at 4°C followed by 5 3
05 cpm/well 125I-labeled goat anti-mouse IgG under the same condi-
ions. As a control untransfected, mock-infected BGMK cells were
nalyzed similarly (BGMK mock).n this cell surface RIA (Fig. 7). rWe then analyzed the intracellular distribution of wild-
ype H-2Ld or a transfected mutant form of H-2Ld (2.2.1
utant) in which the cytoplasmic tail has been deleted
Zu´n˜iga et al., 1983) in mock- and myxoma-infected trans-
ectant BGMK cells (BGMK-Ld and BGMK-2.2.1, respec-
ively). In mock-infected transfectants, the intracellular
istributions of the wild-type H-2Ld and the 2.2.1 mutant
re similar to those of the endogenous MHC I molecules
nd of transferrin receptors of untransfected, mock-in-
ected BGMK cells, a largely perinuclear distribution
compare Figs. 8A and 8D with Figs. 5A and 5C). It is only
n this perinuclear location that either of the transfected
HC I molecules co-localizes with Lamp-1 (Figs. 8A–8F).
yxoma virus infection induces a striking change in the
ocalization of wild-type H-2Ld in BGMK-Ld transfectants.
ittle H-2Ld is found in the Golgi (Figs. 8G and 8I),
resumably due to viral effects on MHC I biosynthesis,
s mentioned above. Rather, in myxoma-infected trans-
ectants, wild-type H-2Ld occurs in Lamp-11 vesicular
tructures (Figs. 8G–8I), as is the case with endogenous
HC I (Figs. 5D, 5F, and 5H). In contrast, the 2.2.1 mutant
f H-2Ld does not localize in Lamp-11 vesicular struc-
ures in myxoma-infected cells (Figs. 8J–8L). Hence the
-2Ld cytoplasmic tail appears to be required for myxo-
a-induced localization into Lamp-11 structures.
The localization of MHC I molecules in Lamp-11 struc-
ures in myxoma-infected cells is reminiscent of the ef-
ects of inhibitors of the vacuolar ATPases, CCA, and Baf
1 on MHC I molecules (Zu´n˜iga et al., 1999). Baf and
CA lead to the loss of MHC I from the cell surface in
GMK cells (Zu´n˜iga et al., 1999). We examined the dis-
ribution of H-2Ld and the 2.2.1 mutant of H-2Ld in unin-
ected, CCA-treated transfectant BGMK cells (Figs. 8M–
R). In parallel, we examined the intracellular distribution
f the endogenous MHC I molecules and of transferrin
eceptors in untransfected, CCA-treated BGMK (Fig. 9). A
omparison of untreated (Figs. 8A–8C) and CCA-treated
GMK-Ld transfectants shows that CCA causes some of
he H-2Ld to localize into swollen, Lamp-11 vesicles
Figs. 8M–8O). Note, however, that H-2Ld also occurs in
perinuclear distribution (Figs. 8M–8O), consistent with
he fact that CCA has no effect on protein synthesis or on
he transport of newly synthesized MHC I through the
ecretory pathway (Zu´n˜iga et al., 1999). In untransfected
GMK cells, the endogenous MHC I molecules occurs in
amp-11 vesicles, although perinuclearly distributed
HC I is also evident (Figs. 9A–9C), demonstrating that
his effect is not unique to the transfected H-2Ld mole-
ule. Because CCA causes a loss of cell surface MHC I
ithout preventing delivery of newly synthesized MHC I
o the cell surface (Zu´n˜iga et al., 1999), these results
ndicate that the majority of MHC I found in Lamp-11
esicles are derived from the cell surface.
In CCA-treated BGMK-2.2.1 transfectants, the tail-less
-2Ld molecule is not found in Lamp-11 vesicles butather co-localizes only with perinuclearly distributed
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187DEGRADATION OF CELL-SURFACE CLASS I MHCamp-1 (Figs. 8P–8R). Similarly, transferrin receptor in
CA-treated BGMK cells does not cluster into vesicular
tructures but remains largely perinuclearly distributed
compare Figs. 9D and 9E). The fact that the tail-less
-2Ld mutant escapes both myxoma-induced and CCA-
nduced localization in late endosomes/lysosomes sug-
ests that the cytoplasmic tail contains the structural
nformation necessary for targeting it to such compart-
ents in response to these agents. In light of the abro-
ation of various steps in membrane protein recycling by
af and CCA (Clague et al., 1994; Reaves and Banting,
994; van Weert et al., 1995; Woo et al., 1992a), these
bservations are consistent with the possibility that in-
ibitors of vacuolar ATPase prevent the return of endo-
ytosed MHC I to the cell surface in BGMK cells in a
ytoplasmic domain-dependent fashion. More to the
oint of this report, the observations that both vacuolar
TPase inhibitors and myxoma induce the localization of
ntact MHC I, but not of tail-less MHC I or transferrin
eceptor, into Lamp-11 structures are consistent with the
ossibility that myxoma is affecting cell surface proteins
hat use specific endocytic trafficking pathways.
DISCUSSION
Here we show that in cells infected with the myxoma
irus, MHC I molecules are lost from the cell surface in
time-dependent fashion. MHC I molecules accumulate
n Lamp-11 late endosomes and/or lysosomes of in-
ected cells and are degraded therein. MHC I degrada-
ion is rescued by leupeptin, vacuolar ATPase inhibitors,
nd by NH4Cl but not by proteasome inhibitors, consis-
ent with degradation by lysosomal-type proteases. Al-
hough NH4Cl rescues MHC I degradation, it does not
escue cell surface display of MHC I (Figs. 4B and 4D).
ecause NH4Cl does not cause a loss of cell surface
HC I in uninfected cells (Fig. 4D), the failure of rescued
HC I molecules to return to the cell surface is likely to
e due to virally induced retention mechanisms.
The MHC I cytoplasmic domain is required for its
ocalization in late endosomes/lysosomes in cells
reated with inhibitors of vacuolar ATPases or infected
ith myxoma virus (Fig. 8). The observation that myxoma
irus induces the degradation of monkey, mouse, and
abbit MHC I molecules in monkey and rabbit cell lines
ogether with the failure of myxoma virus to promote
edistribution of tail-less MHC I molecules and of trans-
errin receptors suggests that the mechanism used by
yxoma virus exploits the normal trafficking patterns of
ormal MHC I molecules. Viral gene products may op-
rate on conserved components of the cellular transport
achinery or may interact with conserved features of
HC I molecules. The former possibility is favored by the
act that cell surface CD4 also is lost in myxoma-infected
abbit RL-5 cells and that this effect also is dependent on
arly, but not late, viral gene products (Barry et al., 1995). eMHC I retention in Lamp-11 late endosomes and ly-
osomes and its degradation therein are refractory to
ra-C (Figs. 3A, 3B, and 6), thus implicating early gene
roducts in these effects. How many different viral gene
roducts are required for these processes is uncertain. It
s possible that only one is required, as appears to be the
ase for two other viruses. The gp48 protein of mouse
ytomegalovirus associates with MHC I molecules in the
R and reroutes them to lysosomes for degradation
Reusch et al., 1999). Nef protein, an early gene product
f HIV-1, down-regulates cell surface levels of MHC I
Schwartz et al., 1996) and CD4 (Luo et al., 1996; Man-
asarian et al., 1997) by affecting their trafficking from the
rans-Golgi network and promoting their endocytosis
rom the cell surface. Although superficially the myxoma-
nd Nef-induced losses of MHC I are similar, the rela-
ively slow kinetics of MHC I down-regulation from the
ell surface and of its degradation suggest the myxoma
ene product operates in a different manner from that
sed by the Nef protein.
Intracellular retention and degradation of post-Golgi
HC I molecules are not the only mechanisms by which
yxoma virus down-regulates cell surface MHC I. In fact,
R-resident unassembled MHC I molecules also are
nstable in myxoma-infected cells (Zu´n˜iga et al., 1999).
owever, at 6 h p.i., MHC I molecules are still trans-
orted out of the ER and through the Golgi apparatus
M.C.Z. and H.W., unpublished observations). Hence,
arly in infection, MHC I molecules can still be loaded
ith peptides, some of which are of viral origin, and be
isplayed at the cell surface. It is possible that the
yxoma-induced sequestration of post-Golgi MHC I mol-
cules in late endosomes/lysosomes and their subse-
uent degradation therein provides the virus with a
eans of dispensing with MHC I molecules that were
oaded with peptides early in infection, whereas the
nterference with the assembly and transport of ER-res-
dent MHC I, which is not maximal until later in infection,
revents the presentation of peptides produced late in
nfection. In this way, myxoma virus may effectively es-
ape CTLs specific for viral epitopes generated through-
ut the viral infectious cycle. Even so, it is striking that at
east in the cell lines used in these studies, MHC I
own-regulation is not evident until 12 h p.i. and is not
aximal until 24 h p.i. Perhaps the kinetics of MHC I
own-regulation in BGMK cells is slower than is the case
n vivo. Alternatively, myxoma virus infection may have
ffects on the cellular trafficking machinery itself, as
uggested above. In this case, the down-regulation of
HC I molecule would not be unique to MHC I mole-
ules, would affect all cell surface proteins that traffic
imilarly to MHC I molecules, and would be a secondary
ffect of viral infection. Another possibility is that this
henomenon is restricted to these cell lines and is not
haracteristic of myxoma infection in primary cells. Rep-
tition of these studies in myxoma-infected primary cells
c
M
o
F
a
iFIG. 8. Wild-type but not tail-less H-2Ld molecules are retained in late endosomes/lysosomes in myxoma-infected or CCA-treated cells. BGMK-Ld
ells (A–C and G–I) or BGMK-2.2.1 cells (D–F and J–L) were mock infected (A–F) or infected with 10 PFU/cell vMyxlac (G–L) for 24 h. (M–R)
ock-infected BGMK-Ld (M–O) or BGMK-2.2.1 (P–R) transfectants were treated with 25 nM CCA for 3 h. Cells were then processed for immunoflu-
rescence microscopy as described in Materials and Methods. Then b2-m-associated H-2L
d molecules were detected with MAb 30.5.7, followed by
ITC-GAMIG (A, D, G, J, M, and P), and Lamp-1 was detected with anti-Lamp-1, followed by Rh-GARIG (B, E, H, K, N, and Q) as described in Materials
nd Methods. (C, F, I, L, O, and R) Each panel shows merged images of Lamp-1 and of wild-type H-2Ld or the 2.2.1 mutant of H-2Ld staining shownn the panels in the same row. The scale bar represents 25 mm.
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189DEGRADATION OF CELL-SURFACE CLASS I MHCr possibly in other cell lines should establish the in vivo
elevance of the observations reported herein.
Cloning of myxoma virus genes required for the intra-
ellular retention and degradation of MHC I will allow the
etermination of their roles in promoting a productive
nfection in vivo. Moreover, these viral genes may prove
o be useful molecular tools for elucidating the role of
HC I cycling to and from the cell surface in its function
s an antigen presenting molecule.
MATERIALS AND METHODS
ells and viruses
The BGMK cell line was grown in RPMI 1640 medium
upplemented with 10% FBS, and the rabbit kidney cell
ine RK-13 was grown in MEM containing 10% FBS. In all
xperiments, cells were infected at a multiplicity of in-
ection of 10 PFU/cell with myxoma virus engineered with
he Escherichia coli LacZ gene inserted at an innocuous
ite between the virus growth factor and the M9 gene
vMyxlac) (Opgenorth et al., 1992). Efficiency of infection
as routinely assessed by monitoring the percentage of
ells expressing LacZ. Briefly, the cells were fixed for 5
in on ice with 0.2% glutaraldehyde and 2% formalde-
yde in PBS, pH 7.2; washed with PBS; and incubated in
taining solution (5 mM potassium ferricyanide, 5 mM
otassium ferrocyanide, 0.1% X-gal, 2 mM MgCl2 in PBS)
or 20 min at 37°C. The efficiency of infection was cal-
ulated as the ratio of infected (blue) cells relative to the
FIG. 9. MHC I molecules but not TRs accumulate in late endosomes
ntreated (D) or treated with 25 nM CCA for 3 h (A–C and E). Cells
aterials and Methods. The b2-m-associated MHC I molecules were d
ith anti-Lamp-1, followed by Rh-GARIG (B); and TRs were detected
escribed in Materials and Methods. (C) Merged image of MHC I (A)otal. Ieagents
RPMI 1640, MEM, FBS, and trypsin were purchased
rom JRH Biosciences (Woodland, CA). LIPOFECTIN Re-
gent and G418 were obtained from GIBCO (Gaithers-
urg, MD). Ara-C, saponin, and protein A–Sepharose
ere purchased from Sigma Chemical Co. (St. Louis,
O). Protein standards (Kaleidoscope) were from Bio-
ad (Hercules, CA). EXPRE35S35S protein labeling mix
as purchased from Dupont NEN (Boston, MA). Baf A1
nd CCA were from Wako Chemicals (Richmond, VA).
-gal was purchased from Research Products Interna-
ional Corp. (Mt. Prospect, IL).
ntibodies
MAb 30.5.7 (Ozato et al., 1980), specific for b2-m-
ssociated H-2Ld, was purified from hybridoma culture
upernatants by protein A–Sepharose affinity chromatog-
aphy. MAbs W6/32 (Barnstable et al., 1978) specific for
2-m-associated MHC I molecules were provided by Dr.
eter Parham. MAb anti-61, specific for rabbit MHC I (Le
uern et al., 1987), was the kind gift of Dr. Tom Kindt.
abbit anti-human Lamp-1 antiserum (Carlsson et al.,
988) was a gift of Dr. Minoru Fukuda. Anti-transferrin
eceptor MAb was purchased from Zymed Laboratories,
nc. (South San Francisco, CA). Goat anti-mouse IgG was
btained from Santa Cruz Biotechnology, Inc. (Santa
ruz, CA). Fluorescein-labeled goat anti-mouse IgG
FITC-GAMIG) and rhodamine-labeled goat anti-rabbit
mes in CCA-treated cells. Untransfected, uninfected BGMK cells were
hen processed for immunofluorescence microscopy as described in
with MAb W6/32, followed by FITC-GAMIG (A); Lamp-1 was detected
nti-transferrin receptor MAb, followed by FITC-GAMIG (D and E) as
Lamp-1 (B) staining. The scale bar represents 25 mm./lysoso
were t
etected
with agG (Rh-GARIG) were purchased from ICN-Cappel
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190 ZU´N˜IGA ET AL.Durham, NC). (R)-Phycoerythrin-conjugated F(ab9)2 goat
nti-mouse IgG was from DAKO (Carpenteria, CA).
ell surface RIA
GAMIG was radioiodinated IODO-GEN reagent.
riefly, 50 mg of immunoglobulin and 0.5 mCi of Na125I
ere mixed with 100 ml of PBS and added immediately to
test tube coated with 10 mg of IODO-GEN. The reaction
as allowed to proceed at room temperature for 10 min,
nd the reaction mixture was loaded onto a 3-ml column
f Sephadex G-50 column to separate immunoglobulin
rom free Na125I. 20 fractions of 3 drops each were col-
ected, and 1 ml of each fraction was counted in a gamma
ounter. The fractions containing radioiodinated anti-
ody were combined and used for future experiments.
his antibody reagent was used in the second step of a
wo-step cell surface RIA with W6/32 or MAb 30.5.7 in the
irst step as described previously (Zu´n˜iga and Hood,
986) and in the legend to Fig. 1.
low cytometry
Flow cytometric analyses were performed on nonper-
eabilized and permeabilized cells as described previ-
usly (Barry et al., 1995; Boshkovet al., 1992). Briefly,
GMK cells were infected with vMyxlac for the times
ndicated in the figure legends, harvested, washed, and
tained at a concentration of 1.25 3 107 cells/ml. For the
tudies shown in Fig. 4, NH4Cl was added to cells to a
oncentration of 40 mM at 1 h p.i. Staining was achieved
ith MAb W6/32 followed by (R)-phycoerythrin-conju-
ated F(ab9)2 goat anti-mouse IgG. For measurement of
otal MHC I, cells were fixed in 1% in PBS and then
ermeabilized in 1% saponin in PBS before incubation
ith antibodies. After the second antibody incubation,
ells were washed and fixed again with 1% paraformal-
ehyde. Flow cytometric analysis was performed on a
ecton Dickinson FACScan instrument (Mountain View,
A) equipped with an argon ion laser with 15 mW of
xcitation at 488 nm. The standard optical filter assembly
as 530/30 band pass, 585/42 band pass, and 650 long
ass filter.
ransfection of BGMK cells
Expression constructs containing wild-type H-2Ld and
he 2.2.1 tail-less mutant of H-2Ld have been described
reviously (Zu´n˜iga et al., 1983). These constructs were
ntroduced into BGMK cells with the LIPOFECTIN re-
gent according to the manufacturer’s instructions. Sta-
le transfectants were selected in RPMI 1640 supple-
ented with 10% FBS and 600 mg/ml G418.
etabolic labeling of cells and SDS–PAGE
Biosynthetic labeling and pulse-chase studies were
erformed as described previously (Capps et al., 1993; tu´n˜iga et al., 1983) and as described in the figure leg-
nds; 5 3 106 cells/condition were used. Cells were
ashed three times with PBS, lysed, and prepared for
mmunoprecipitation as described previously. Immuno-
recipitated proteins were resolved electrophoretically
y SDS–PAGE as described previously.
mmunofluorescence microscopy
Cells were plated onto Lab Tek multichamber slide
lasks (Nunc, Inc., Naperville, IL) the day before immu-
ofluorescence imagining in the confocal microscope.
n the day of the analysis, cells were rinsed with wash
uffer [80 mM piperazine-N,N9-bis(2-ethanesulfonic ac-
d)/KOH, pH 6.8, 5 mM EGTA, 2.0 mM MgCl2] and then
ixed for 15 min at room temperature with 4% paraformal-
ehyde freshly dissolved in wash buffer. Fixation was
uenched for 10 min at room temperature with quench-
ng buffer (75 mM NH4Cl, 20 mM glycine in PBS, pH 8.0).
ells were washed three times with PBS. Permeabiliza-
ion and blocking were carried out for 60 min at 37°C in
locking buffer (3% BSA, 1% normal goat serum, 0.025%
aponin in PBS, pH 7.2). Then b2-m-associated MHC I
olecules were detected with the specific MAb indi-
ated in the figure legend, followed by FITC-GAMIG.
amp-1 was detected with rabbit anti-Lamp-1, followed
y Rh-GARIG. Transferrin receptor was detected with
nti-transferrin receptor MAb, followed by FITC-GAMIG.
ncubation with antibodies diluted in blocking buffer was
or 60 min at 37°C. After each incubation, cells were
ashed three times with blocking buffer, once with PBS
ontaining 0.025% saponin, and then once again with
locking buffer. After the last incubation, cells were
ashed with PBS, incubated with 0.1% Triton X-100 in
BS for 5 min at room temperature, and washed for 5 min
n PBS. Cells were fixed again in 4% paraformaldehyde
issolved in 100 mM Na-cacodylate, pH 7.4, for 30 min at
oom temperature; washed with PBS; and visualized by
onfocal microscopy using an Olympus IMT2 inverted
hotoscope equipped with a BioRad 600 laser confocal
magining system. Imaging was achieved with an Olym-
us S plan APO 603 oil objective.
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